4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonists.

Cancer Commun (Lond) · 2024 · PMC11483270 · PMID 39097973

Europe PMC DOI

hedged sentence

0.0740

closest p · 1.5× alpha

0.0740

boldest claim

The sentences

showed a trendP = 0.074so close (0.05 < p ≤ 0.1)

In patients treated with immunotherapy ( n = 217), the high 4‐1BB group ( n = 39) showed a trend towards longer progression‐free survival (PFS) (HR = 0.70, 95%CI: 0.47‐1.04, P = 0.074; Figure 1J ) and significantly longer OS (HR = 0.55, 95%CI: 0.33‐0.89, P = 0.016; Figure 1K ) compared to the low/moderate 4‐1BB group ( n = 178) (calculated from start of immunotherapy).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.